Bayosthiti AI, a pioneer in AI-driven healthcare and molecular diagnostics, has partnered with Narayana Health, one of the world’s largest cardiac care networks, to develop advanced AI models for predicting cardiovascular disease in Indian patients. The partnership integrates RNA sequencing with generative AI to detect heart disease risk earlier and more accurately than traditional diagnostic methods.
Transforming Cardiovascular Risk Prediction through RNA Sequencing
As per the press release, the joint study will analyze transcriptomic data—the complete set of active RNA messages in cells—from more than 12,000 participants at the Narayana Institute of Cardiac Sciences in Bengaluru. Using Bayosthiti’s proprietary BIRT™ (Barcode-Integrated Reverse Transcription) technology, researchers will sequence entire RNA profiles from patient blood samples. The AI models will then be trained to identify molecular patterns that indicate coronary artery disease long before conventional tests can detect abnormalities.
Bridging the ‘Data Gap’ in Indian Cardiac Health
Coronary artery disease affects over 65 million Indians and often strikes at younger ages compared to Western populations. However, existing diagnostic tools are primarily based on European and American datasets, leaving a significant “Data Gap.” This gap causes risk assessment tools to overlook subtle biological patterns unique to South Asian populations, leading to delayed diagnoses and fewer treatment options.
Leveraging Molecular Innovation and Clinical Scale
Narayana Health’s extensive clinical reach—performing more than 60,000 cardiac procedures annually—provides a robust foundation for AI model training. Meanwhile, Bayosthiti’s BIRT™ technology reduces sequencing costs by processing multiple samples simultaneously. This innovation makes large-scale RNA sequencing feasible and cost-effective, enabling the creation of AI models precisely tuned to Indian genetic and environmental contexts.
Moving from Reactive to Predictive Medicine
Unlike imaging or protein-based diagnostics that detect disease after it manifests physically, RNA sequencing captures the real-time molecular activity within cells. By analyzing which genes are actively transcribed and at what levels, Bayosthiti’s AI can detect early biological shifts toward disease—potentially months or even years before structural damage occurs.
Harnessing AI to Decode the Body’s Molecular Language
“Just as Google Translate learned language patterns from billions of text examples, our AI learns disease patterns from millions of RNA expressions,” explained Dr. Rishabh M. Shetty, Head of Business Development and Clinical Applications at Bayosthiti AI. “Our models can identify the molecular dialogue that precedes a heart attack, not just its aftermath—offering accuracy comparable to invasive or imaging-based diagnostics.”
Validating AI through Clinical Excellence
With its credibility and scale, Narayana Health serves as the ideal validation partner for this initiative. Dr. P.M. Uthappa, Group Chief Medical Director at Narayana Health, emphasized, “AI-based technologies aren’t the future—they’re the present. This collaboration helps us shift from intervention to prevention, giving clinicians the ability to identify high-risk patients earlier and more precisely.”
Building India’s Foundation for Personalized Medicine
Since launching operations in India, Bayosthiti AI has collaborated with over 100 partners worldwide. This latest project marks a major expansion in both scope and impact. Kutapa Muthanna, CEO of Bayosthiti AI, stated, “We’ve relied too long on Western models of medicine. This partnership builds the foundation for proactive, personalized healthcare created by Indians, for Indians. When we can detect heart disease risk before any visible blockage appears, we redefine preventive care.”
Paving the Way for Broader Healthcare Applications
The partnership follows a three-phase study design, allowing continuous model refinement. Upon successful validation, these AI models could pave the way for similar predictive tools targeting other major diseases in India. Ultimately, the findings will guide the development of an affordable, blood-based diagnostic test deployable nationwide—marking a significant step toward AI-powered preventive medicine in India.